|
Video: What is a Stock Split?
|
|
Alimera Sciences is a pharmaceutical company that focuses in the commercialization and development of ophthalmic pharmaceuticals. Co. focuses on diseases affecting the retina. Co.'s commercial product is ILUVIEN®, an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide in the eye, for up to 36 months. ILUVIEN is also used in certain countries in the European Economic Area to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. LUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a needle, which allows for a self-sealing wound. According to our ALIM split history records, Alimera Sciences has had 1 split. | |
|
Alimera Sciences (ALIM) has 1 split in our ALIM split history database. The split for ALIM took place on November 15, 2019. This was a 1 for 15 reverse split, meaning for each 15 shares of ALIM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Alimera Sciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ALIM split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Alimera Sciences shares, starting with a $10,000 purchase of ALIM, presented on a split-history-adjusted basis factoring in the complete ALIM split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/28/2014 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$90.45 |
|
End price/share: |
$3.63 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.99% |
|
Average Annual Total Return: |
-27.50% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$401.57 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
11/15/2019 | 1 for 15 |
|
|